Novartis | NOVN - Interest Expense On Debt


Novartis reported $462M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alcon AG USD 52M 2M Mar/2026
Amgen USD 95.64B 94.98B Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Autolus Therapeutics Ltd USD 11.12M 11.71M Mar/2026
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 407M 4M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 79M 6M Mar/2026
Genmab DKK 10M 27M Dec/2025
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
J&J USD 43M 25M Mar/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 104M 17M Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 462M 119M Jun/2026
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.5B 28M Jun/2026
Orion EUR 700K 700K Jun/2026
Pfizer USD 667M 4M Jun/2026
Philips EUR 83M 26M Mar/2026
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
UCB EUR 49M 29M Dec/2025